Table 2

Univariate Analysis of Survival
UNIVARIATE ANALYSIS OF SURVIVAL
Variable MST 1-year survival % P-value
Age Category ≤ 60 16.50 53.00% 0.591
>60 15.75 47.86%
Gender Male 15.75 50.34% 0.515
Female 16.50 49.3%
60-70 11.75 30.30%
Karnofsky PS 80 16.75 52.40% <0.001
90-100 19.25 63.20%
1 14.50 36.40% 0.092
Histological Grade 2 17.25 54.30%
3 14.25 44.87%
Lymph node metastasis No 13.50 28.89% 0.051
Yes 16.75 56.65%
Liver metastasis No 19.25 63.39% <0.001
Yes 12.75 37.74%
Lung metastasis No 16.25 52.24% 0.185
Yes 12.75 35.29%
Ovarian metastasis No 16.00 51.27% 0.579
Yes 17.00 47.62%
Bone metastasis No 16.25 51.18% 0.282
Yes 12.25 42.86%
Peritoneal dissemination No 16.75 54.90% 0.319
Yes 15.00 43.70%
Albumin Normal 18.00 57.66% 0.002
Low 12.75 38.30%
CRP Normal 18.00 56.06% <0.001
High 12.75 43.02%
HP No 15.50 48.59% 0.35
Yes 17.25 52.63%
CEA ≤ 5 15.00 45.54% 0.143
> 5 17.00 52.83%
CA 19-9 ≤ 30 18.25 58.14% 0.019
> 30 14.50 46.21%
CA 72-4 ≤ 7 21.75 65.00% 0.002
> 7 14.75 47.46%
Low 22.50 73.86%
DNA Index Medium 12.75 35.20% <0.001
High 09.50 23.81%

MST Median Survival Time, PS Performance Status, CRP C-Reactive Protein, HP Helicobacter Pylori, CEA Carcinoembryonic Antigen, CA 19–9 Cancer Antigen 19–9, CA 72–4 Cancer Antigen 72–4.

Syrios et al.

Syrios et al. BMC Cancer 2012 12:264   doi:10.1186/1471-2407-12-264

Open Data